Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PARP inhibitor

AstraZeneca AZ

AstraZeneca escapes pandemic impact as new drugs bolster revenues

Earnings climbed above expectations in the second quarter

- PMLiVE

AZ strengthens Daiichi Sankyo partnership with new ADC deal

Deal for experimental antibody drug conjugate could reach $6bn

AstraZeneca AZ

Emergent inks $174m deal with AstraZeneca to manufacture COVID-19 vaccine

Follows initial deal agreed in June

AstraZeneca AZ

AZ/Oxford’s COVID-19 vaccine proves promising in early trials

Vaccine candidate produced robust immune response

- PMLiVE

AstraZeneca’s Farxiga scores another FDA fast-track designation

Company is aiming for approval in prevention indication

AstraZeneca AZ

AstraZeneca’s Brilinta reduces rate of secondary stroke

Drug helps to prevent rate of stroke and death by 17%

AstraZeneca AZ

EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

PARP inhibitor now available for rare, life-threatening disease

- PMLiVE

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

Antibody drug conjugate gained approval in US in December

AstraZeneca AZ

AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq

First checkpoint inhibitor to challenge Roche's Tecentriq in this indication

AstraZeneca AZ

AstraZeneca forms $2bn gene silencing pact with Silence Tx

Collaboration focuses on cardiovascular, renal, metabolic and respiratory disease

- PMLiVE

China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

China secures a place at the forefront of innovative medicine

AstraZeneca AZ

AZ’s Imfinzi plus tremelimumab combo misses again

Drug missed endpoint in small cell lung cancer trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links